Session Description:

This session will explore emerging advances in mesenchymal stromal cell (MSC) biology and translation into therapies for pulmonary disease, alongside innovations in gene delivery to the lung. With insights from immunology, regenerative medicine, and gene therapy, speakers will highlight how these approaches are moving toward effective clinical applications.

Session Objectives:

• Examine how advances in MSC biology and immune interactions inform therapeutic mechanisms in lung disease.
• Understand how microenvironmental and intrinsic cellular factors influence MSC potency, consistency, and clinical outcomes.
• Evaluate current progress in manufacturing and gene delivery strategies that support scalable, effective therapies for pulmonary indications.

Session Description:

This session highlights cutting-edge advances in gene editing from engineered cellular systems to first-in-human personalised therapies. Speakers will showcase how synthetic biology, CAR T reprogramming, and in vivo gene editing will enable highly precise and adaptable treatments for cancer and rare genetic disease.

Session Objectives:

• Understand how synthetic biology and gene editing are being used to design next-generation cellular and antibody-based therapies.
• Explore innovative gene-editing strategies to rewire CAR T cells for improved specificity, function, and tumour-restricted activity.
• Evaluate emerging in vivo gene-editing approaches, including rapid, patient-specific therapies for rare genetic disorders, and their implications for future clinical translation.

Session Description:

This session will highlight emerging off-the-shelf and engineered cell therapy strategies for transplantation and immunotherapy. Featuring advances in cord blood expansion, exosome-based immunotherapy, and novel allogeneic platforms, speakers will demonstrate how scalable, accessible treatments are reshaping care for cancer and other immune-mediated diseases.

Session Objectives:

• Explore how cord blood–derived and other allogeneic platforms are enabling off-the-shelf cell therapies for transplantation and cancer treatment.
• Examine innovative approaches such as exosome-based immunotherapies and engineered cell products to improve tumour targeting, safety, and cost-effectiveness.
• Understand how expanded and engineered cell platforms can enhance engraftment, immune recovery, and anti-tumour responses.

Session Description:

This session will showcase next-generation immunotherapy strategies focused on engineering T cells to improve safety, durability, and efficacy across both haematological malignancies and solid tumours. In addition, advances in transplant-integrated cellular therapies, including engineered donor T cells and strategies to enhance graft-versus-tumour effects while minimising graft-versus-host disease, will highlight how immunotherapy and transplant biology will expand treatment options.

Session Objectives:

• Understand how next-generation T-cell engineering is being designed to overcome current limitations in safety, persistence, and tumour targeting.
• Explore emerging strategies to extend immunotherapy effectiveness in solid tumours and resistant cancers.
• Examine how transplant engineering approaches, including modified donor T-cell therapies, are improving outcomes and shaping the future integration of immunotherapy and haematopoietic cell transplantation.